Status:
COMPLETED
A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
Lead Sponsor:
Kunming Medical University
Collaborating Sponsors:
Chinese Academy of Sciences
Conditions:
Depression
Depression Secondary to Other Disease
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The purpose of this study is: 1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD); 2. find special abnormalities i...
Detailed Description
1. to explore the pathology of depression 2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease 3. to explore the effect of gene-environmen...
Eligibility Criteria
Inclusion
- DSM-IV Major Depression or Dysthymia
- Age 18-65
- Physically healthy
- Drug-free
Exclusion
- Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
- History of Psychosis or Epilepsy
- Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
- Bipolar I
- Need for wash-out from effective treatment in order to participate
- Pregnant
- High suicide risk
- Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00703742
Start Date
June 1 2008
End Date
June 1 2011
Last Update
September 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China, 650031